No Data
No Data
Boundless Bio Downgraded to Neutral at Guggenheim After BBI-825 Scrapped
Boundless Bio Analyst Ratings
Guggenheim Downgrades Boundless Bio to Neutral From Buy
Guggenheim Initiates Boundless Bio(BOLD.US) With Hold Rating
Express News | Boundless Bio Inc : Leerink Partners Cuts Target Price to $15 From $21
Boundless Bio to Discontinue Clinical Trial Related to Solid Tumors
No Data
73264095 : Nice, thanks! You think UMAC is done? looked like it held up pretty well in AH
Jaguar8 OP 73264095 : Nope. I feel it will still go
Jaguar8 OP 73264095 : I have not yet finished the list
Huaw : Will the rejection of APLT approval cause such a significant decline? Is it this serious?
Jaguar8 OP Huaw : It was just a CRL meaning they can’t approve at the moment due to some deficiencies which the company will address and will resubmit
View more comments...